Key Points
- Adaptive Biotechnologies CFO Kyle Piskel sold 3,115 shares on May 18 at an average price of $13.04, for a total of $40,619.60. The sale was disclosed to the SEC and was tied to tax withholding from vesting equity awards.
- The company reported stronger-than-expected first-quarter results, posting EPS of -$0.13 versus estimates of -$0.16 and revenue of $70.87 million versus $61.03 million expected. Revenue rose 35.1% year over year.
- Wall Street sentiment is mixed but generally positive, with six Buy ratings, one Hold, and one Sell, and a consensus price target of $19.57. Shares opened at $13.96, below the average analyst target.
Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) CFO Kyle Piskel sold 3,115 shares of the firm's stock in a transaction on Monday, May 18th. The shares were sold at an average price of $13.04, for a total value of $40,619.60. Following the completion of the sale, the chief financial officer directly owned 256,725 shares in the company, valued at approximately $3,347,694. This represents a 1.20% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Kyle Piskel also recently made the following trade(s):
- On Wednesday, March 11th, Kyle Piskel sold 18,672 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.17, for a total value of $245,910.24.
Adaptive Biotechnologies Stock Performance
Shares of ADPT stock opened at $13.96 on Thursday. The stock's fifty day moving average price is $13.81 and its two-hundred day moving average price is $15.65. The company has a market cap of $2.23 billion, a PE ratio of -42.30 and a beta of 2.16. Adaptive Biotechnologies Corporation has a fifty-two week low of $8.50 and a fifty-two week high of $20.76.
Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last issued its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.16) by $0.03. The firm had revenue of $70.87 million for the quarter, compared to the consensus estimate of $61.03 million. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.The company's revenue was up 35.1% compared to the same quarter last year. During the same quarter last year, the business posted ($0.20) EPS. On average, equities analysts predict that Adaptive Biotechnologies Corporation will post -0.48 EPS for the current fiscal year.
Analyst Ratings Changes
A number of brokerages have recently commented on ADPT. Piper Sandler set a $21.00 price target on Adaptive Biotechnologies in a research note on Friday, February 6th. Wall Street Zen cut Adaptive Biotechnologies from a "buy" rating to a "hold" rating in a research note on Saturday, March 7th. Morgan Stanley dropped their price target on Adaptive Biotechnologies from $21.00 to $18.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 12th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Adaptive Biotechnologies in a research note on Monday, April 20th. Finally, BTIG Research reiterated a "buy" rating and issued a $22.00 price target on shares of Adaptive Biotechnologies in a research note on Wednesday, May 6th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Adaptive Biotechnologies presently has an average rating of "Moderate Buy" and a consensus price target of $19.57.
Get Our Latest Analysis on ADPT
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd bought a new position in shares of Adaptive Biotechnologies in the 4th quarter valued at $28,000. EverSource Wealth Advisors LLC raised its position in Adaptive Biotechnologies by 197.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company's stock worth $38,000 after purchasing an additional 1,565 shares during the last quarter. Assetmark Inc. raised its position in Adaptive Biotechnologies by 867.9% during the 4th quarter. Assetmark Inc. now owns 3,020 shares of the company's stock worth $49,000 after purchasing an additional 2,708 shares during the last quarter. T. Rowe Price Investment Management Inc. bought a new position in Adaptive Biotechnologies during the 4th quarter worth $51,000. Finally, Strive Financial Group LLC bought a new position in Adaptive Biotechnologies during the 4th quarter worth $52,000. 99.17% of the stock is currently owned by institutional investors.
About Adaptive Biotechnologies
(
Get Free Report)
Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.
The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
